These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7587052)

  • 1. Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime.
    Turnidge JD
    Diagn Microbiol Infect Dis; 1995; 22(1-2):57-69. PubMed ID: 7587052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefotaxime in healthy volunteers and patients.
    Patel KB; Nicolau DP; Nightingale CH; Quintiliani R
    Diagn Microbiol Infect Dis; 1995; 22(1-2):49-55. PubMed ID: 7587050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK; Ostergaard BE; Rotschafer JC
    Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics.
    Nix DE; Schentag JJ
    Diagn Microbiol Infect Dis; 1995; 22(1-2):71-6. PubMed ID: 7587053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-gm infusions.
    Goodpasture HC; Gerlach EH; Jones RN; Peterie JD
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):97-103. PubMed ID: 3383550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cefotaxime in the treatment of surgical infections.
    Wittmann DH
    Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations.
    Wilson WR; Bouza E; Lode H; Mouton Y
    J Chemother; 1997 May; 9 Suppl 2():5-18. PubMed ID: 9248972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
    Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.
    Craig WA
    Diagn Microbiol Infect Dis; 1995; 22(1-2):89-96. PubMed ID: 7587056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
    Jones RN; Thornsberry C
    Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
    Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro activity of a new 3d-generation cephalosporin, cefodizime, on hospital bacteria].
    Soussy CJ; Otterbein G; Le Van Thoi J; Duval J; Chanal M; Cluzel M; Sirot D
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):561-6. PubMed ID: 3534743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
    Dulaney Lopez AM; Rodriguez JC; Lopez-Samblas AM; Estes KS
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
    Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
    J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia.
    Soriano F; Ponte C; Nieto E; Parra A
    J Antimicrob Chemother; 1996 Aug; 38(2):227-36. PubMed ID: 8877536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.
    Kays MB; White RL; Friedrich LV; Del Bene VE
    Clin Ther; 1991; 13(5):596-605. PubMed ID: 1799917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefotaxime: microbiology, pharmacology, and clinical use.
    Dudley MN; Barriere SL
    Clin Pharm; 1982; 1(2):114-24. PubMed ID: 6309465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.